MCID: PYR010
MIFTS: 50

Peyronie's Disease

Categories: Reproductive diseases

Aliases & Classifications for Peyronie's Disease

MalaCards integrated aliases for Peyronie's Disease:

Name: Peyronie's Disease 40 12 15
Induratio Penis Plastica 12 32
Peyronie Disease 12 71
Balanitis Xerotica Obliterans 71
Peyronie's Fibromatosis 12
Peyronies Disease 40
Penile Induration 43

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD9CM 34 607.85
MeSH 43 D010411
NCIt 49 C3316
SNOMED-CT 67 1335005
ICD10 32 N48.6
UMLS 71 C0030848 C0152460

Summaries for Peyronie's Disease

MalaCards based summary : Peyronie's Disease, also known as induratio penis plastica, is related to peyronie disease and keloid disorder. An important gene associated with Peyronie's Disease is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include prostate, small intestine and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Peyronie's Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 peyronie disease 33.2 TGFB1 IFNA2
2 keloid disorder 30.8 TGFB1 SMAD3
3 dupuytren contracture 30.4 TGFB1 DCN
4 hypertrophic scars 30.3 TGFB3 TGFB1 SMAD3
5 idiopathic interstitial pneumonia 30.3 TGFB1 SMAD3 CCL2
6 carcinoid syndrome 30.0 IGF1 IFNA2
7 pulmonary fibrosis 29.8 TGFB1 SMAD7 SMAD3 CCL2
8 penile disease 29.3 TGFB1 IL6 IFNA2 IFNA1
9 ulcerative colitis 29.0 SMAD7 SMAD4 SMAD3 IL6
10 colitis 29.0 SMAD7 SMAD4 SMAD3 IL6
11 bone disease 28.7 IL6 IGF1 DCN CCL2
12 autoimmune disease 28.6 TGFB1 IL6 IFNA1 HLA-A CCL2
13 pulmonary fibrosis, idiopathic 28.3 TGFB1 SMAD7 SMAD4 SMAD3 IL6 CCL2
14 ledderhose disease 11.3
15 impotence 11.2
16 sexual disorder 10.7
17 varicocele 10.5
18 cutaneous polyarteritis nodosa 10.5 SMAD3 IFNA2
19 corneal intraepithelial neoplasm 10.4 IFNA2 IFNA1
20 lymphomatoid granulomatosis 10.4 IFNA2 IFNA1
21 cryoglobulinemia, familial mixed 10.4 IFNA2 IFNA1
22 hydrocele 10.4
23 vascular disease 10.4
24 fibromatosis 10.4
25 stiff skin syndrome 10.4 TGFB2 TGFB1
26 fibrosis of extraocular muscles, congenital, 1 10.3
27 tuberculoid leprosy 10.3 TGFB3 TGFB2 TGFB1
28 aneurysm 10.3 TGFB3 TGFB2 SMAD3
29 hypercholesterolemia, familial, 1 10.3
30 lipid metabolism disorder 10.3
31 loeys-dietz syndrome 5 10.3 TGFB3 TGFB2 SMAD3
32 loeys-dietz syndrome 3 10.3 TGFB3 TGFB2 SMAD3
33 loeys-dietz syndrome 4 10.3 TGFB3 TGFB2 SMAD3
34 discoid lupus erythematosus 10.3 IFNA2 IFNA1
35 loeys-dietz syndrome 1 10.3 TGFB3 TGFB2 SMAD3
36 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
37 prostatitis 10.2
38 plague 10.2
39 mucositis 10.2 TGFB3 TGFB1 IFNA1
40 scleroderma, familial progressive 10.2
41 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
42 sarcoma 10.2
43 spindle cell sarcoma 10.2
44 epithelioid sarcoma 10.2
45 diabetes mellitus 10.2
46 cytokine deficiency 10.2
47 obstructive nephropathy 10.2 TGFB1 SMAD3 CCL2
48 vitreoretinopathy, neovascular inflammatory 10.2 TGFB2 TGFB1 CCL2
49 hereditary hemorrhagic telangiectasia 10.2 TGFB2 TGFB1 SMAD4
50 orthostatic intolerance 10.1 TGFB2 SMAD3 DCN

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

GenomeRNAi Phenotypes related to Peyronie's Disease according to GeneCards Suite gene sharing:

26 (show all 28)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.85 HLA-A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.85 IFNA1 IFNA2 TGFB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.85 HLA-A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.85 IFNA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.85 HLA-A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.85 TGFB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.85 IFNA2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.85 TGFB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.85 TGFB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.85 IFNA1 IFNA2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.85 TGFB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.85 HLA-A IFNA1 IFNA2 TGFB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.85 HLA-A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.85 TGFB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.85 IFNA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.85 IFNA2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.85 IFNA2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.85 HLA-A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.85 TGFB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.85 TGFB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.85 IFNA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.85 HLA-A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.85 IFNA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.85 HLA-A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.85 TGFB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.85 IFNA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.85 IFNA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.85 IFNA1

MGI Mouse Phenotypes related to Peyronie's Disease:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 DCN IGF1 IL6 MSTN PTN SMAD3
2 cardiovascular system MP:0005385 10.26 IGF1 IL6 MSTN SMAD3 SMAD4 SMAD7
3 growth/size/body region MP:0005378 10.24 DCN IGF1 IL6 MSTN SMAD3 SMAD4
4 homeostasis/metabolism MP:0005376 10.23 DCN IGF1 IL6 MSTN PTN SMAD3
5 immune system MP:0005387 10.21 CCL2 DCN IGF1 IL6 MSTN PTN
6 digestive/alimentary MP:0005381 10.18 DCN IL6 MSTN SMAD3 SMAD4 SMAD7
7 hematopoietic system MP:0005397 10.18 DCN IGF1 IL6 PTN SMAD3 SMAD4
8 endocrine/exocrine gland MP:0005379 10.16 DCN IGF1 IL6 SMAD3 SMAD4 SMAD7
9 craniofacial MP:0005382 10.14 DCN MSTN SMAD3 SMAD4 SMAD7 TGFB1
10 muscle MP:0005369 9.97 DCN IGF1 IL6 MSTN SMAD4 SMAD7
11 limbs/digits/tail MP:0005371 9.88 IGF1 MSTN SMAD3 SMAD4 TGFB2 TGFB3
12 renal/urinary system MP:0005367 9.86 DCN IGF1 IL6 MSTN SMAD3 SMAD4
13 reproductive system MP:0005389 9.85 DCN IGF1 IL6 PTN SMAD3 SMAD4
14 neoplasm MP:0002006 9.8 DCN IGF1 IL6 SMAD3 SMAD4 TGFB1
15 respiratory system MP:0005388 9.5 DCN IGF1 IL6 TGFB1 TGFB2 TGFB3
16 skeleton MP:0005390 9.28 DCN IGF1 IL6 MSTN SMAD3 SMAD4

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
3
Testosterone enanthate Approved Phase 4 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
5
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
6 Phosphodiesterase 5 Inhibitors Phase 4
7 Vasodilator Agents Phase 4
8 Phosphodiesterase Inhibitors Phase 4
9 Vardenafil Dihydrochloride Phase 4
10 Anabolic Agents Phase 4
11 Hormone Antagonists Phase 4
12 Testosterone 17 beta-cypionate Phase 4
13 Antineoplastic Agents, Hormonal Phase 4
14 Androgens Phase 4
15 Hormones Phase 4
16 Neurotransmitter Agents Phase 4
17 Anti-Arrhythmia Agents Phase 4
18 Adrenergic Antagonists Phase 4
19 Adrenergic beta-Antagonists Phase 4
20 Sodium Channel Blockers Phase 4
21 Autonomic Agents Phase 4
22 Diuretics, Potassium Sparing Phase 4
23 Sympatholytics Phase 4
24 Adrenergic Agents Phase 4
25
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
26
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
27
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
28
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
29
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
30
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
31 abobotulinumtoxinA Phase 2
32 Pharmaceutical Solutions Phase 2
33 Acetylcholine Release Inhibitors Phase 2
34 Neuromuscular Agents Phase 2
35 Botulinum Toxins Phase 2
36 Cholinergic Agents Phase 2
37 Botulinum Toxins, Type A Phase 2
38 Liver Extracts Phase 1, Phase 2
39 Citrate Phase 1, Phase 2
40 Sildenafil Citrate Phase 1, Phase 2 171599-83-0
41 Chlorhexidine gluconate Phase 2
42 Dermatologic Agents Phase 2
43 Anti-Infective Agents, Local Phase 2
44 Disinfectants Phase 2
45 Analgesics Phase 2
46 Anti-Infective Agents Phase 2
47
Tocopherol Approved, Investigational Phase 1 1406-66-2, 54-28-4 14986
48
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
2 A Phase 4, Single-Center, Multiple-Dose, Open-Label Trial to Evaluate the Efficacy of Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response After Prior Xiaflex® Treatment Recruiting NCT03767452 Phase 4 Xiaflex® 0.58 mg
3 Treatment Response to Xiaflex Based on Ultrasound Characterization of Plaque for Men With Peyronie's Disease Recruiting NCT03774264 Phase 4 Xiaflex
4 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol A Six-month, Pilot Project of Testosterone Treatment in Subjects Who Are Undergoing Xiaflex® Therapy for the Treatment of Peyronie's Disease Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
5 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
6 A Phase 3b, Open-label Pilot Study to Evaluate the Safety and Effectiveness of up to Four Treatment Cycles of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Men With Peyronie's Disease Completed NCT02267460 Phase 3
7 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01243411 Phase 3
8 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
9 A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01221597 Phase 3
10 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01221623 Phase 3
11 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
12 The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease Unknown status NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
13 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) - a Randomized Trial Unknown status NCT01184586 Phase 2
14 To Study The Proof of Concept in The Improvement of Cognition and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy by Means of a Pharmacological Intervention With Sildenafil (A Phosphodiesterase-5 Inhibitor). Unknown status NCT02028429 Phase 1, Phase 2 Sildenafil.
15 A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
16 A Phase 2, Open-Label Study to Assess the Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
17 Management of Urethral Injury During Penile Prosthesis Implantation: Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair and Same-Session Implantation Recruiting NCT03614429 Phase 2 Chlorhexidine gel will be prepared according to an international product Instillagel®
18 A Sequential, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Safety and Efficacy of the H-100 Treatment in Adult Male Volunteers With Peyronie's Disease Completed NCT02072018 Phase 1 H-100;Placebo
19 An Open-Label, Nine-Month Randomized Controlled Study of Testosterone (Testopel) Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
20 Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease Completed NCT02395029 Phase 1
21 The Role of Adipose Tissue Stem Cell Injection Through Corpora Cavernosa and Intra Dorsal Penile Artery in Management of Erectile Dysfunction Associated With Peyronie's Disease Unknown status NCT02414308 Adipose tissue stem cell injection
22 A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy Unknown status NCT03192917
23 The Efficacy of Extracorporal Shock Wave Therapy on Symptoms Relief in Patients With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
24 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806 Completed NCT02298829 Subjects Previously Treated with AA4500
25 Circumcision Versus Preputioplasty for BXO in Children: A Feasibility Randomised Controlled Trial Completed NCT02854995
26 Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse Completed NCT04052217
27 Efficacy of Penile Traction Therapy Using a Novel Device: A Controlled, Single-blinded, Randomized Trial Completed NCT03389854
28 Assessing the Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
29 Extracorporeal Shockwave Therapy (ESWT) of Chronic Diabetic Foot Ulcers Completed NCT02251418
30 A Prospective Randomized Double Blinded Placebo Controlled Clinical Trial Evaluating the Combined Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) and Vacuum Erectile Device Combined With Manipulation Exercises on Peyronies Disease. Recruiting NCT03530540
31 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419
32 Local Injection of Collagenase Clostridium Histolyticum (XiapexR) for Refractory Iatrogenic Esophageal Strictures: an Open-label Pilot Study Recruiting NCT03898661 Early Phase 1 Collagenase histiolyticum
33 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

40
Prostate, Small Intestine, Bone, Heart, Liver, Lung, T Cells

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 1917)
# Title Authors PMID Year
1
Evolution of the surgical sealing patch TachoSil® in Peyronie's disease reconstructive surgery: technique and contemporary literature review. 61
31053920 2020
2
Re: Increased Risk of Cancer in Men with Peyronie's Disease: A Cohort Study Using a Large United States Insurance Claims Database. 61
31710537 2020
3
A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease results in reduced procedural morbidity using a standardized hematoma classification rubric. 61
31152197 2020
4
Managing complications of collagenase Clostridium histolyticum (CCH) injection. 61
31123850 2020
5
Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond. 61
31168744 2020
6
A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie's disease. 61
31190155 2020
7
Radiation Therapy for Benign Disease: Keloids, Macular Degeneration, Orbital Pseudotumor, Pterygium, Peyronie Disease, Trigeminal Neuralgia. 61
31739946 2020
8
Safety of Collagenase Clostridium histolyticum Injection Therapy for Peyronie Disease in Patients Continuing Antiplatelet or Anticoagulant Therapy. 61
31866126 2020
9
Clinical Recommendations From the European Society for Sexual Medicine Exploring Partner Expectations, Satisfaction in Male and Phalloplasty Cohorts, the Impact of Penile Length, Girth and Implant Type, Reservoir Placement, and the Influence of Comorbidities and Social Circumstances. 61
31812683 2020
10
Peyronie's disease in contemporary urological practice. 61
31853627 2020
11
Diagnostic utility of penile ultrasound in Peyronie's disease. 61
31606787 2020
12
Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: a review of the literature. 61
31250098 2020
13
Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase. 61
31093703 2020
14
Contemporary Thoughts on the Role of Shockwave Therapy in Peyronie's Disease. 61
31992436 2020
15
Verapamil and collagenase differentially affect collagen metabolism in experimental model of Peyronie's disease. 61
31733276 2020
16
Current trends in the surgical treatment of congenital penile curvature. 61
31383991 2020
17
Risk profiling in patients undergoing penile prosthesis implantation. 61
31489849 2020
18
Platelet-Rich Plasma Therapy for Male Sexual Dysfunction: Myth or Reality? 61
30898594 2020
19
Editorial Comment: Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie's Disease in an Era of Effective Clinical Treatment. 61
31851473 2020
20
Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study. 61
32009312 2020
21
Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie's disease using the modified shortened protocol: Results from a retrospective analysis. 61
32003061 2020
22
Re: Comparison of Clinician and Patient Users of a Mobile Phone Application to Assess Penile Curvature in Peyronie's Disease. 61
31625787 2020
23
Peyronie's Disease Intervention Studies: An Exploration of Modern-Era Challenges in Study Design and Evaluating Treatment Outcomes. 61
31932258 2020
24
Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease. 61
31922462 2020
25
Corrigendum to 'Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's Disease'. 61
31732145 2020
26
Intraoperative methods for residual curvature correction during penile prosthesis implantation in patients with Peyronie's disease and refractory erectile dysfunction. 61
31754245 2020
27
Additional procedures performed at time of penile prosthesis implantation: a review of current literature. 61
30705435 2020
28
Long-term patient-reported outcomes in men with Peyronie's disease undergoing nonsurgical and nonintralesional injection management. 61
31988423 2020
29
Is modeling an inflatable penile prosthesis obsolete for patients with Peyronie's disease? 61
31992871 2020
30
Prevalence, Risk Factors, and Erectile Dysfunction Associated With Peyronie's Disease Among Men Seeking Urological Care. 61
32007472 2020
31
Novel approaches and new grafting materials in Peyronie's disease reconstructive surgery. 61
31383990 2020
32
Modern treatment strategies for penile prosthetics in Peyronie's disease: a contemporary clinical review. 61
31424027 2020
33
Strategies and current practices for penile lengthening in severe Peyronie's disease cases: a systematic review. 61
31481708 2020
34
Editorial Comment: Surgical Management of Peyronie's Disease With Co-Existent Erectile Dysfunction. 61
31851472 2020
35
Re: Outcomes of Surgery in Peyronie's Disease following Intralesional Collagenase Clostridium histolyticum Injections. 61
31625788 2020
36
Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease. 61
31628593 2020
37
Noninvasive Treatment Options for Peyronie's Disease. 61
31983573 2020
38
Plication techniques in Peyronie's disease: new developments. 61
31582822 2020
39
Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function. 61
29623703 2020
40
Urologic conditions associated with malignancy. 61
30611645 2020
41
Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis. 61
31870487 2020
42
Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis. 61
31759930 2020
43
How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy? 61
31190485 2020
44
Re: Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts across Europe. 61
31512977 2019
45
Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease. 61
31445974 2019
46
Increased Risk of Cancer in Men With Peyronie's Disease: A Cohort Study Using a Large United States Insurance Claims Database. 61
31530474 2019
47
Surgical Management of Peyronie's Disease With Co-Existent Erectile Dysfunction. 61
31540882 2019
48
Re: Plication Techniques in Peyronie's Disease: New Developments. 61
31821076 2019
49
Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling. 61
31033130 2019
50
Long-Term Follow-Up After Penile Prosthesis Implantation-Survival and Quality of Life Outcomes. 61
31501062 2019

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
2
Show member pathways
13.73 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
3
Show member pathways
13.72 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 MSTN
4
Show member pathways
13.59 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
5
Show member pathways
13.49 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4 SMAD3
6
Show member pathways
13.44 TGFB3 TGFB2 TGFB1 PTN IL6 IGF1
7
Show member pathways
13.34 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 PTN
8
Show member pathways
13.32 TGFB3 TGFB2 TGFB1 IGF1 IFNA2 IFNA1
9
Show member pathways
13.32 WNT2 TGFB3 TGFB2 TGFB1 PTN IL6
10
Show member pathways
13.17 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
11
Show member pathways
13.12 TGFB3 TGFB2 TGFB1 PTN IL6 IGF1
12
Show member pathways
13.11 TGFB3 TGFB2 TGFB1 PTN IL6 IGF1
13
Show member pathways
13.04 WNT2 IL6 IGF1 IFNA2 IFNA1 HLA-A
14
Show member pathways
12.95 IL6 IFNA2 IFNA1 HLA-A CCL2
15
Show member pathways
12.93 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IGF1
16
Show member pathways
12.9 TGFB3 TGFB2 TGFB1 IL6 IGF1
17
Show member pathways
12.89 TGFB1 IL6 IFNA2 IFNA1 HLA-A
18
Show member pathways
12.85 IL6 IFNA2 IFNA1 HLA-A CCL2
19 12.84 IL6 IFNA2 IFNA1 HLA-A CCL2
20
Show member pathways
12.83 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
21
Show member pathways
12.78 TGFB3 TGFB2 TGFB1 PTN IL6 IGF1
22
Show member pathways
12.68 TGFB3 TGFB2 TGFB1 IL6 IGF1
23
Show member pathways
12.67 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
24
Show member pathways
12.55 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
25
Show member pathways
12.48 TGFB3 TGFB2 TGFB1 PTN IL6 IGF1
26 12.46 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
27 12.4 WNT2 TGFB2 TGFB1 IGF1 DCN
28 12.39 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
29 12.38 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
30
Show member pathways
12.35 TGFB1 SMAD7 SMAD4 SMAD3
31
Show member pathways
12.34 TGFB3 TGFB2 TGFB1 IL6 IGF1
32 12.33 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
33 12.32 TGFB3 TGFB2 TGFB1 IL6 IFNA2 IFNA1
34 12.3 IL6 IFNA2 IFNA1 CCL2
35
Show member pathways
12.28 TGFB2 TGFB1 SMAD4 SMAD3
36 12.26 TGFB3 TGFB2 TGFB1 SMAD3 IL6 HLA-A
37
Show member pathways
12.21 WNT2 TGFB1 SMAD3 IL6 IGF1
38 12.19 WNT2 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
39 12.17 WNT2 SMAD4 SMAD3 IGF1
40 12.14 TGFB1 SMAD7 SMAD4 SMAD3
41 12.14 WNT2 TGFB1 IL6 IGF1
42 12.14 TGFB1 SMAD3 IL6 IGF1
43
Show member pathways
12.14 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
44 12.1 WNT2 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4
45 12.07 WNT2 TGFB1 SMAD4 SMAD3
46 12.03 TGFB1 SMAD4 SMAD3 IL6 IGF1
47 12.02 TGFB1 IL6 CCL2
48 12.02 TGFB3 TGFB2 TGFB1 IL6
49
Show member pathways
12.02 TGFB3 TGFB2 TGFB1 PTN IL6 IGF1
50
Show member pathways
12 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 WNT2 TGFB3 TGFB2 TGFB1 PTN MSTN
2 collagen-containing extracellular matrix GO:0062023 9.63 WNT2 TGFB3 TGFB2 TGFB1 IFNA2 DCN
3 platelet alpha granule lumen GO:0031093 9.56 TGFB3 TGFB2 TGFB1 IGF1
4 extracellular space GO:0005615 9.4 WNT2 TGFB3 TGFB2 TGFB1 PTN MSTN
5 SMAD protein complex GO:0071141 9.32 SMAD4 SMAD3

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 WNT2 TGFB3 TGFB1 SMAD7 SMAD4 SMAD3
2 negative regulation of cell proliferation GO:0008285 10.14 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3 IL6
3 positive regulation of cell proliferation GO:0008284 10.14 WNT2 TGFB3 TGFB2 TGFB1 PTN IL6
4 cytokine-mediated signaling pathway GO:0019221 10.07 TGFB1 IL6 IFNA2 IFNA1 CCL2
5 regulation of apoptotic process GO:0042981 10.03 TGFB3 TGFB2 TGFB1 MSTN
6 negative regulation of gene expression GO:0010629 10.03 TGFB2 TGFB1 IGF1 IFNA2
7 response to hypoxia GO:0001666 10.03 TGFB3 TGFB2 TGFB1 SMAD4 SMAD3
8 regulation of cell proliferation GO:0042127 10.01 TGFB3 TGFB2 TGFB1 SMAD4
9 positive regulation of transcription, DNA-templated GO:0045893 10.01 TGFB3 TGFB1 SMAD4 SMAD3 MSTN IL6
10 platelet degranulation GO:0002576 9.98 TGFB3 TGFB2 TGFB1 IGF1
11 negative regulation of cell growth GO:0030308 9.98 TGFB2 TGFB1 SMAD4 SMAD3
12 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.96 TGFB3 TGFB1 SMAD7 SMAD3
13 cellular response to transforming growth factor beta stimulus GO:0071560 9.94 WNT2 TGFB1 SMAD7 SMAD3
14 regulation of MAPK cascade GO:0043408 9.93 TGFB3 TGFB2 TGFB1 MSTN
15 kidney development GO:0001822 9.92 TGFB2 SMAD4 DCN
16 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 WNT2 SMAD3 IL6
17 humoral immune response GO:0006959 9.92 IL6 IFNA2 IFNA1 CCL2
18 cell development GO:0048468 9.92 TGFB3 TGFB2 TGFB1 MSTN
19 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.91 TGFB1 IL6 IGF1
20 positive regulation of cell division GO:0051781 9.91 TGFB3 TGFB2 TGFB1 PTN
21 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.9 TGFB2 IGF1 DCN
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IL6 IGF1 IFNA2
23 cellular response to organic cyclic compound GO:0071407 9.9 TGFB1 PTN CCL2
24 type I interferon signaling pathway GO:0060337 9.9 IFNA2 IFNA1 HLA-A
25 positive regulation of protein secretion GO:0050714 9.9 TGFB3 TGFB2 TGFB1 IGF1
26 negative regulation of epithelial cell proliferation GO:0050680 9.89 TGFB2 TGFB1 PTN
27 inner ear development GO:0048839 9.89 TGFB3 TGFB2 TGFB1
28 wound healing GO:0042060 9.89 TGFB3 TGFB2 TGFB1 SMAD3 DCN
29 positive regulation of fibroblast proliferation GO:0048146 9.88 WNT2 TGFB1 IGF1
30 negative regulation of fat cell differentiation GO:0045599 9.88 TGFB1 SMAD3 IL6
31 BMP signaling pathway GO:0030509 9.88 TGFB3 TGFB2 TGFB1 SMAD7 SMAD4
32 extrinsic apoptotic signaling pathway GO:0097191 9.87 TGFB2 TGFB1 SMAD3
33 ureteric bud development GO:0001657 9.87 TGFB1 SMAD7 SMAD3
34 protein kinase B signaling GO:0043491 9.87 TGFB1 IGF1 CCL2
35 response to progesterone GO:0032570 9.87 TGFB3 TGFB2 TGFB1 PTN
36 ventricular septum morphogenesis GO:0060412 9.86 TGFB2 SMAD7 SMAD4
37 endoderm development GO:0007492 9.86 TGFB1 SMAD4 SMAD3
38 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.86 TGFB2 TGFB1 SMAD3
39 positive regulation of bone mineralization GO:0030501 9.85 TGFB3 TGFB1 SMAD3 PTN
40 secondary palate development GO:0062009 9.83 TGFB3 TGFB2 SMAD4
41 pathway-restricted SMAD protein phosphorylation GO:0060389 9.82 TGFB2 TGFB1 SMAD7
42 positive regulation of SMAD protein signal transduction GO:0060391 9.81 TGFB3 TGFB1 SMAD4
43 salivary gland morphogenesis GO:0007435 9.79 TGFB3 TGFB2 TGFB1
44 response to laminar fluid shear stress GO:0034616 9.76 TGFB3 TGFB1 SMAD7
45 interleukin-6-mediated signaling pathway GO:0070102 9.75 SMAD4 IL6
46 cell growth GO:0016049 9.75 TGFB3 TGFB2 TGFB1
47 positive regulation of transcription regulatory region DNA binding GO:2000679 9.74 TGFB1 IGF1
48 negative regulation of immune response GO:0050777 9.74 TGFB2 TGFB1
49 positive regulation of ossification GO:0045778 9.74 TGFB2 PTN
50 cardiac epithelial to mesenchymal transition GO:0060317 9.74 WNT2 TGFB2

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen binding GO:0005518 9.71 SMAD7 SMAD4 SMAD3 DCN
2 transforming growth factor beta receptor binding GO:0005160 9.55 TGFB3 TGFB2 TGFB1 SMAD3 MSTN
3 type I transforming growth factor beta receptor binding GO:0034713 9.54 TGFB3 TGFB1 SMAD7
4 type II transforming growth factor beta receptor binding GO:0005114 9.5 TGFB3 TGFB2 TGFB1
5 growth factor activity GO:0008083 9.5 TGFB3 TGFB2 TGFB1 PTN MSTN IL6
6 type I interferon receptor binding GO:0005132 9.46 IFNA2 IFNA1
7 I-SMAD binding GO:0070411 9.43 SMAD7 SMAD4
8 type III transforming growth factor beta receptor binding GO:0034714 9.43 TGFB3 TGFB2 TGFB1
9 cytokine activity GO:0005125 9.28 WNT2 TGFB3 TGFB2 TGFB1 MSTN IL6

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....